For: | Cheng CW, Leong KW, Tse E. Understanding the role of PIN1 in hepatocellular carcinoma. World J Gastroenterol 2016; 22(45): 9921-9932 [PMID: 28018099 DOI: 10.3748/wjg.v22.i45.9921] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v22/i45/9921.htm |
Number | Citing Articles |
1 |
Liang Zhang, Yi Huang, Junjun Ling, Wenlei Zhuo, Zhen Yu, Mengmeng Shao, Yunbo Luo, Yi Zhu. Screening and function analysis of hub genes and pathways in hepatocellular carcinoma via bioinformatics approaches. Cancer Biomarkers 2018; 22(3): 511 doi: 10.3233/CBM-171160
|
2 |
Jichuang Wang, Nan Zhang, Qi Han, Wenxian Lu, Long Wang, Dayun Yang, Min Zheng, Zhenzhen Zhang, Hekun Liu, Tae Ho Lee, Xiao Zhen Zhou, Kun Ping Lu. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. Cancer Letters 2019; 444: 82 doi: 10.1016/j.canlet.2018.12.010
|
3 |
Guo Yan-Tong, Lu Yan, Jia Yi-Yang, Qu Hui-Nan, Qi Da, Wang Xin-Qi, Song Pei-Ye, Jin Xiang-Shu, Xu Wen-Hong, Dong Yuan, Liang Ying-Ying, Quan Cheng-Shi. Predictive Value of Pin1 in Cervical Low-Grade Squamous Intraepithelial Lesions and Inhibition of Pin1 Exerts Potent Anticancer Activity against Human Cervical Cancer. Aging and disease 2020; 11(1): 44 doi: 10.14336/AD.2019.0415
|
4 |
Dana Grunhaus, Assaf Friedler, Mattan Hurevich. Automated Synthesis of Heavily Phosphorylated Peptides. European Journal of Organic Chemistry 2021; 2021(26): 3737 doi: 10.1002/ejoc.202100691
|
5 |
Wang Wang, Qizhou Jiang, Jiaxin Tao, Zhenxian Zhang, GuoPing Liu, Binxuan Qiu, Qingyang Hu, Yuxi Zhang, Chao Xie, Jiawen Song, GuoZhen Jiang, Hui Zhong, Yanling Zou, Jiaqi Li, Shaoli lv. A structure-based approach to discover a potential isomerase Pin1 inhibitor for cancer therapy using computational simulation and biological studies. Computational Biology and Chemistry 2025; 114: 108290 doi: 10.1016/j.compbiolchem.2024.108290
|
6 |
Yang Chen, Ya-ran Wu, Hong-ying Yang, Xin-zhe Li, Meng-meng Jie, Chang-jiang Hu, Yu-yun Wu, Shi-ming Yang, Ying-bin Yang. Prolyl isomerase Pin1: a promoter of cancer and a target for therapy. Cell Death & Disease 2018; 9(9) doi: 10.1038/s41419-018-0844-y
|
7 |
Sanghamitra Mylavarapu, Harsh Kumar, Smita Kumari, L. S. Sravanthi, Misti Jain, Aninda Basu, Manjusha Biswas, Sivaram V. S. Mylavarapu, Asmita Das, Monideepa Roy. Activation of Epithelial-Mesenchymal Transition and Altered β-Catenin Signaling in a Novel Indian Colorectal Carcinoma Cell Line. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00054
|
8 |
Dingding Han, Penggao Yang, Bo Qin, Guoqing Ji, Yanhua Wu, Long Yu, Hong Zhang. Upregulation of Nogo‐B by hypoxia inducible factor‐1 and activator protein‐1 in hepatocellular carcinoma. Cancer Science 2021; 112(7): 2728 doi: 10.1111/cas.14941
|
9 |
Machi Kanna, Yusuke Nakatsu, Takeshi Yamamotoya, Jeffrey Encinas, Hisanaka Ito, Takayoshi Okabe, Tomoichiro Asano, Takemasa Sakaguchi. Roles of peptidyl prolyl isomerase Pin1 in viral propagation. Frontiers in Cell and Developmental Biology 2022; 10 doi: 10.3389/fcell.2022.1005325
|
10 |
Kai Liu, Minying Zheng, Rui Lu, Jiaxing Du, Qi Zhao, Zugui Li, Yuwei Li, Shiwu Zhang. The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review. Cancer Cell International 2020; 20(1) doi: 10.1186/s12935-020-01304-w
|
11 |
Yunchuan Kong, Tianwei Yu, Jonathan Wren. A graph-embedded deep feedforward network for disease outcome classification and feature selection using gene expression data. Bioinformatics 2018; 34(21): 3727 doi: 10.1093/bioinformatics/bty429
|
12 |
Kai Jiang, Ning Ning, Jing Huang, Yu Chang, Rao Wang, Jie Ma. Psilostachyin C reduces malignant properties of hepatocellular carcinoma cells by blocking CREBBP-mediated transcription of GATAD2B. Functional & Integrative Genomics 2024; 24(2) doi: 10.1007/s10142-024-01353-8
|
13 |
玮 戚. Correlation between Pin1 and Bladder Cancer. Advances in Clinical Medicine 2022; 12(03): 2403 doi: 10.12677/ACM.2022.123347
|
14 |
S. G. Khoei, C. Mohammadi, Y. Mohammadi, S. Sameri, R. Najafi. Prognostic value of peptidyl-prolyl cis–trans isomerase 1 (PIN1) in human malignant tumors. Clinical and Translational Oncology 2020; 22(7): 1067 doi: 10.1007/s12094-019-02233-5
|
15 |
Honghao Zhang, Jianyu Chen, Yabo Meng, Qingyan Cen, Hao Wang, Xiangyang Ding, Kexin Ai, Yulu Yang, Yang Gao, Yingqi Qiu, Yuxing Hu, Meifang Li, Yanjie He, Yuhua Li. Overexpression of Pin1 regulated by TOP2A, which subsequently stabilizes Pyk2 to promote bortezomib resistance in multiple myeloma. Cancer Gene Therapy 2025; 32(1): 22 doi: 10.1038/s41417-024-00845-w
|
16 |
GuoFei Zhu, ShaoLi Lyu, Yang Liu, Chao Ma, Wang Wang, Vincenza Crupi. Investigation on the Binding and Conformational Change of All-trans-Retinoic Acid with Peptidyl Prolyl cis/trans Isomerase Pin1 Using Spectroscopic and Computational Techniques. Journal of Spectroscopy 2021; 2021: 1 doi: 10.1155/2021/1012078
|
17 |
Julián Maggio, Maia Cabrera, Romina Armando, Patricio Chinestrad, Marina Pifano, Pablo Lorenzano Menna, Daniel E. Gomez, Diego L. Mengual Gómez. Rational design of PIN1 inhibitors for cancer treatment based on conformational diversity analysis and docking based virtual screening. Journal of Biomolecular Structure and Dynamics 2022; 40(13): 5858 doi: 10.1080/07391102.2021.1874531
|
18 |
Chuanfeng Liu, Lingying Dan, Quan Li, Ousman Bajinka, Xingxing Yuan. The mechanisms of Pin1 as targets for cancer therapy. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1482088
|
19 |
Jung-Soo Pyo, Byoung Kwan Son, Il Hwan Oh. Cytoplasmic Pin1 expression is correlated with poor prognosis in colorectal cancer. Pathology - Research and Practice 2018; 214(11): 1848 doi: 10.1016/j.prp.2018.09.018
|